文献速递系统性红斑狼疮

联合分子表型细分系统性红斑狼疮:两项III期随机试验中的差异人群

Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究利用干扰素(IFN)、抗dsDNA抗体、C3和C4四种分子生物标志物的组合,对两项III期随机试验中的1747例系统性红斑狼疮(SLE)患者进行亚组分类。SLE(+)定义为IFN高、抗dsDNA(+)、C3低和/或C4低;SLE(-)需满足IFN低、抗dsDNA(-)、C3正常且C4正常。SLE(-)组皮肤黏膜和肌肉骨骼表现更多,SLE(+)组血液、肾脏和血管受累更多;SLE(-)组严重复发时间显著更长(P<0.0001),SRI-4应答率显著更低(P=0.00016)。

要点

  • 四标志物组合可区分SLE患者亚群,SLE(-)组严重复发更晚但SRI-4应答更低。
  • SLE(-)组基线皮肤黏膜和肌肉骨骼病变更常见,激素和免疫抑制剂使用更少(MTX除外)。
  • 美国SLE(-)患者比例(22%)高于墨西哥/中美/南美(10%)、欧洲(7%)和世界其他地区(5%)。

核心结论

  • 四种分子生物标志物组合分析可区分SLE患者亚群,这些亚群在疾病表现、合并用药、地理分布、严重复发时间和SRI-4应答上存在差异,可能有助于临床试验设计和患者亚组分析。

研究设计与样本

  • 研究基于两项随机III期试验,共纳入2262例患者,其中1747例有基线IFN、抗dsDNA、C3和C4数据。
  • 采用二分分类方案:SLE(+)定义为IFN高、抗dsDNA(+)、C3低和/或C4低;SLE(-)需满足IFN低、抗dsDNA(-)、C3正常且C4正常。

主要发现

  • SLE(-)组247例,SLE(+)组1500例;SLE(-)组基线皮肤黏膜和肌肉骨骼病变更常见,SLE(+)组血液、肾脏和血管受累更多。
  • SLE(-)组激素和免疫抑制剂合并使用更少(MTX除外)。
  • SLE(-)组严重复发时间显著长于SLE(+)组(P<0.0001),SRI-4应答率显著低于SLE(+)组(P=0.00016)。
  • 美国SLE(-)患者比例为22%,高于墨西哥/中美/南美(10%)、欧洲(7%)和世界其他地区(5%)。

关键数值与推荐

  • SLE(+)定义:IFN高、抗dsDNA(+)、C3低和/或C4低。
  • SLE(-)定义:IFN低、抗dsDNA(-)、C3正常且C4正常。

临床怎么用

  • 临床可依据IFN、抗dsDNA、C3和C4状态对SLE患者进行分子表型分层,识别可能对治疗应答不同的亚群。
  • 对于生物标志物阴性(SLE(-))患者,需注意其严重复发风险较低但SRI-4应答率可能更低,临床试验设计时应考虑分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Heterogeneity of SLE patients in clinical trials remains a challenge for developing new therapies. This study used a combinatorial analysis of four molecular biomarkers to define key sources of heterogeneity. METHODS: Combinations of IFN (high/low), anti-dsDNA (+/-) and C3 and C4 (low/normal) were used to subset n = 1747 patients from two randomized phase III trials. A dichotomous classification scheme defined SLE (+) as: IFN (high), anti-dsDNA (+), C3 (low) and/or C4 (low). SLE (-) required all of the following: IFN (low), anti-dsDNA (-), C3 (normal) and C4 (normal). Additional analyses subset the data further by IFN, anti-dsDNA and complement. RESULTS: The trials enrolled n = 2262 patients of which n = 1747 patients had data for IFN, anti-dsDNA, C3 and C4 at baseline. There were n = 247 patients in the SLE (-) population and n = 1500 patients in the SLE (+) population. The SLE (-) population had more mucocutaneous and musculoskeletal disease at baseline, while SLE (+) had more haematological, renal and vascular involvement. There was lower concomitant medication use in the SLE (-) population for corticosteroids and immunosuppressants, except for MTX. Time to severe flare was significantly longer in SLE (-) vs SLE (+) (P < 0.0001) and SRI-4 response rate was significantly lower in SLE (-) vs SLE (+) (P = 0.00016). The USA had more SLE (-) patients (22%) than Mexico/Central America/South America (10%), Europe (7%) and the rest of the world (5%). CONCLUSION: Combinatorial analysis of four molecular biomarkers revealed subsets of SLE patients that discriminated by disease manifestations, concomitant medication use, geography, time to severe flare and SRI-4 response. These data may be useful for designing clinical trials and identifying subsets of patients for analysis. Rheumatology key messages SLE patients from a P3 trial were categorized by IFN, anti-dsDNA, C3 and C4 status. Patients lacking molecular markers of SLE distinguished from biomarker positive patients on multiple clinical parameters. Biomarker negative patients have distinct disease characteristics that may impact clinical trial outcomes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Petri M, Watts SD, Higgs RE, et al. Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials. Rheumatology (Oxford). 2021. PMID: 33580248. doi:10.1093/rheumatology/keab144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。